Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis
- 1.5k Downloads
Abdominopelvic cancer surgery increases the risk of postoperative venous thromboembolism (VTE). Low-molecular-weight heparin (LMWH) thromboprophylaxis is recommended, and the role of extended thromboprophylaxis (ETP) is controversial. We performed a systematic review to determine the effect of ETP on deep vein thrombosis (DVT), pulmonary embolism (PE), major bleeding, and all-cause mortality after abdominal or pelvic cancer surgery.
A search of the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials was undertaken, and studies were included if they compared extended duration (2–6 weeks) with conventional duration of thromboprophylaxis (2 weeks or less) after cancer surgery. Pooled relative risk (RR) was estimated using a random effects model.
Seven randomized and prospective studies were included, comprising 4807 adult patients. ETP was associated with a significantly reduced incidence of all VTEs [2.6 vs. 5.6 %; RR 0.44, 95 % confidence interval (CI) 0.28–0.70, number needed to treat (NNT) = 39] and proximal DVT (1.4 vs. 2.8 %; RR 0.46, 95 % CI 0.23–0.91, NNT = 71). There was no statistically significant difference in the incidence of symptomatic PE (0.8 vs. 1.3 %; RR 0.56, 95 % CI 0.23–1.40), major bleeding (1.8 vs. 1.0 %; RR 1.19, 95 % CI 0.47–2.97), and all-cause mortality (4.2 vs. 3.6 %; RR 0.79, 95 % CI 0.47–1.33). None of the outcomes differed if randomized trials were analyzed independently.
ETP after abdominal or pelvic surgery for cancer significantly decreased the incidence of all VTEs and proximal DVTs, but had no impact on symptomatic PE, major bleeding, or 3-month mortality. ETP should be routinely considered in the setting of abdominal and pelvic surgery for cancer patients.
KeywordsPulmonary Embolism Deep Vein Thrombosis Major Bleeding National Comprehensive Cancer Network Major Bleeding Event
Agnes Lee and Cynthia Wu received honoraria and consultancy fees from Pfizer and LEO Pharma.
- 2.Kakkar VV, Balibrea JL, Martinez-Gonzalez J, Prandoni P; CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010;8(6):1223–1229.CrossRefPubMedGoogle Scholar
- 4.Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18(17):3078–3083.PubMedGoogle Scholar
- 8.Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecology. 1984;63(1):92–98.Google Scholar
- 12.Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S–277S.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Canadian Agency for Drugs and Technologies in Health. Requirements for health technology assessment template for reports. Ottawa (ON). The Agency; 2008.Google Scholar
- 17.Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: Proceedings of the 3rd symposium on systematic reviews: beyond the basics. Oxford; 2000. p. 3–5.Google Scholar
- 21.Ibrahim N, Norris L, O’Toole S, McHugh T, Saadeh FA, Gleeson N. Does the extended thromboprophylaxis help to reduce the incidence of venous thromboembolism in gynaecological cancer patients? Thromb Res. 2014;133:S224.Google Scholar
- 26.Wells G, Shea B, O’Connell J, Robertson J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 35.NCCN Clinical Practice Guidelines in Oncology. Venous Thromboembolic disease. http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed 12 Dec 2015.